News

New generation of highly selective DPP-4 inhibitors international diabetes expert Professor Ji Linong interprets Shengglitin Phase III clinical data

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2023-05-31
  • Views:0

(Summary description)

New generation of highly selective DPP-4 inhibitors international diabetes expert Professor Ji Linong interprets Shengglitin Phase III clinical data

(Summary description)

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2023-05-31
  • Views:0

Recently, at the 19th Peking University Diabetes Forum, Professor Ji Linong, chairman of the conference and director of the Department of Endocrinology of Peking University People's Hospital, announced the data and results of two Phase III clinical trials of Shengglitin. As a new generation of highly selective DPP-4 inhibitor independently developed by CGeneTech, Shengglitin's clinical results show that compared with similar drugs already on the market, Shengglitin has very good efficacy and safety, and will become a domestic original 1.1 class hypoglycemic new drug for the treatment of type 2 diabetes.


Professor Ji Linong was speaking at the Peking University Diabetes Forum


Shengglietine has been shortlisted in the national 12th Five-Year and 13th five-year "major new drug creation" special. Due to the excellent data demonstrated in the head-to-head Phase I clinical trial with the best product in the market, we were exempted from the phase II clinical trial and entered the phase III clinical trial directly. Prior to the application of NDA, CGeneTech carried out two phase III clinical trials of Shengglitin and Shengglitin combined with metformin in the treatment of Type 2 diabetes in China, led by Professor Linong Ji, director of Endocrinology Department of Peking University People's Hospital, Director of Peking University Diabetes Center, and chairman of the Western Pacific Region of the International Diabetes Alliance.
Two Phase III trials of Shengliptin enrolled nearly 1000 participants. The Shengliptin monotherapy trial enrolled patients with type 2 diabetes who had not been treated with medication, and the Shengliptin plus metformin trial enrolled patients with type 2 diabetes who had been treated with metformin monotherapy. Both were randomized placebo dose-controlled studies. Subjects were randomly assigned to receive placebo, 50mg of Shengliptin, or 100mg of Shengliptin.
The results showed that the reduction of HbA1c in the 50mg and 100mg dose groups at the end of the 24th week was 1.07% and 1.08%, respectively. In Shengglitin combined with metformin, the HBA1c decreased by 1.17% and 1.23% in the 50mg and 100mg dose groups at the end of the 24th week, respectively. At the same time, HBA1c dropped more sharply in patients with higher blood sugar levels in both trials.
In the subsequent 28-week trial of Shengglitin alone and in combination, data showed a sustained and steady reduction of HBA1c in subjects. At the same time, the 100mg dose group (high dose group) compared with placebo group showed good drug safety, and the incidence of adverse reactions was similar to that of placebo group.


Professor Ji Linong was speaking at the Peking University Diabetes Forum


Professor Gillinon said in his clinical summary: "Clinical trial data of Shengglitin 50mg low dose single drug and combination drug showed significant improvement of glycosylated hemoglobin in patients with different years of diabetes history, which has significant clinical significance. The drug also significantly improved beta cell function and reduced systolic blood pressure. In terms of drug safety, no additional safety issues were observed between Shengglitin and placebo. Therefore, Shengagliptin has a very good efficacy and safety, and we hope that it can soon provide more diabetes treatment drugs for our clinicians."
Professor Hong Tianpei, vice Chairman of Endocrinology Branch of Chinese Medical Association, who presided over the forum, also said on the spot: "As a Class 1.1 new drug independently developed by a Chinese company, Shengglitin has shown us very good clinical data, especially the exemption from phase II clinical trials directly into phase III clinical trials, and the impressive comparison between the two dose groups showed lower effective dose and safer advantages, so we look forward to the early launch of this product."
With the increasing popularity of DPP-4 inhibitors in China, the market size of such drugs (all imported) will reach nearly 10 billion yuan in 2022. At present, metformin combined with statins has become the main treatment scheme in the clinical application of type 2 diabetes. According to the research report of Sullivan, the market scale of statins in China will exceed 30 billion yuan by 2030, with a broad market prospect.
Mr. Ding Juping, co-founder and President of CGeneTech, said, "We are very pleased to see the therapeutic effect of Shengglietine developed by our company in clinical phase III, which is half the 'dosage' of 50mg dosage, and is expected to make it the best new hypoglycemic drug of its kind. I hope it can be approved for market as soon as possible, and benefit the vast number of diabetes patients in China as soon as possible."

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO